Cargando…

Estimating the Lifetime Benefits of Treatments for Heart Failure

OBJECTIVES: This study compared ways of describing treatment effects. The objective was to better explain to clinicians and patients what they might expect from a given treatment, not only in terms of relative and absolute risk reduction, but also in projections of long-term survival. BACKGROUND: Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, João Pedro, Docherty, Kieran F., Stienen, Susan, Jhund, Pardeep S., Claggett, Brian L., Solomon, Scott D., Petrie, Mark C., Gregson, John, Pocock, Stuart J., Zannad, Faiez, McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Mini-Focus: Clinical Trial Considerations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720789/ https://www.ncbi.nlm.nih.gov/pubmed/33039448 http://dx.doi.org/10.1016/j.jchf.2020.08.004

Ejemplares similares

Within trial comparison of survival time projections from short‐term follow‐up with long‐term follow‐up findings
por: Ferreira, João Pedro, et al.
Publicado: (2022)

Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
por: Pocock, Stuart J., et al.
Publicado: (2022)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF
por: Mogensen, Ulrik M., et al.
Publicado: (2017)

Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Ostrominski, John W., et al.
Publicado: (2022)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)
por: Mogensen, Ulrik M., et al.
Publicado: (2018)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial
por: Böhm, Michael, et al.
Publicado: (2022)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Serum potassium in the PARADIGM‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis
por: Curtain, James P, et al.
Publicado: (2023)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER‐like endpoint definitions
por: Anker, Stefan D., et al.
Publicado: (2022)

SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
por: Docherty, Kieran F., et al.
Publicado: (2020)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
por: Docherty, Kieran F., et al.
Publicado: (2020)

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

Blood pressure reduction and anti‐hypertensive treatment choice: A post‐hoc analysis of the SPRINT trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

“Death cannot harm the patient: Comparativism and the biased world problem”
por: R. Cooley, Dennis
Publicado: (2020)

Triage of a febrile patient with a rash: a comparison of chickenpox, monkeypox, and smallpox
por: Seguin, Debra, et al.
Publicado: (2004)

Association is not causation: treatment effects cannot be estimated from observational data in heart failure
por: Rush, Christopher J, et al.
Publicado: (2018)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database
por: MacDonald, Michael R., et al.
Publicado: (2010)

A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON‐HF
por: Peikert, Alexander, et al.
Publicado: (2022)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
por: Chatur, Safia, et al.
Publicado: (2023)

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021)

Sex differences in congestive markers in patients hospitalized for acute heart failure
por: Espersen, Caroline, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bttr93dvf5ifbgleqn54343qm8